Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK500761PMID: 29999820
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 722492-56-0
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of ferumoxytol during breastfeeding; however, the drug has been given safely to neonates intravenously as a magnetic resonance contrast agent.[1] An alternate intravenous iron product with more published data on breastfeeding available may be preferred. For additional information on iron use during breastfeeding, see the monograph on Iron Salts.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
References
- 1.
- Little JT, Bookwalter CA. Magnetic resonance safety: Pregnancy and lactation. Magn Reson Imaging Clin N Am 2020;28:509-16. [PubMed: 33040992]
Substance Identification
Substance Name
Ferumoxytol
CAS Registry Number
722492-56-0
Drug Class
Breast Feeding
Lactation
Milk, Human
Contrast Media
Ferric Compounds
Hematinics
Iron Compounds
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Review Emerging applications for ferumoxytol as a contrast agent in MRI.[J Magn Reson Imaging. 2015]Review Emerging applications for ferumoxytol as a contrast agent in MRI.Bashir MR, Bhatti L, Marin D, Nelson RC. J Magn Reson Imaging. 2015 Apr; 41(4):884-98. Epub 2014 Jun 30.
- Brain iron deposition after Ferumoxytol-enhanced MRI: A study of Porcine Brains.[Nanotheranostics. 2020]Brain iron deposition after Ferumoxytol-enhanced MRI: A study of Porcine Brains.Theruvath AJ, Aghighi M, Iv M, Nejadnik H, Lavezo J, Pisani LJ, Daldrup-Link HE. Nanotheranostics. 2020; 4(4):195-200. Epub 2020 Jun 18.
- Review Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease.[Expert Opin Pharmacother. 2009]Review Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease.Coyne DW. Expert Opin Pharmacother. 2009 Oct; 10(15):2563-8.
- FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease.[Am J Hematol. 2010]FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease.Lu M, Cohen MH, Rieves D, Pazdur R. Am J Hematol. 2010 May; 85(5):315-9.
- Review Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease.[J Nephrol. 2011]Review Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease.Kowalczyk M, Banach M, Rysz J. J Nephrol. 2011 Nov-Dec; 24(6):717-22.
- Ferumoxytol - Drugs and Lactation Database (LactMed®)Ferumoxytol - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...